Blar i forfatter "Villatoro, Alicia"

Viser treff 1-4 av 4

    • Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation 

      Villatoro, Alicia; Cuminetti, Vincent; Bernal, Aurora; Torroja, Carlos; Cossío, Itziar; Benguría, Alberto; Ferré, Marc; Konieczny, Joanna; Vázquez, Enrique; Rubio, Andrea; Utnes, Peter Andree; You, Xiaona; Fenton, Christopher Graham; Paulssen, Ruth H; Zhang, Jing; Sánchez-Cabo, Fatima; Dopazo, Ana; Vik, Anders; Anderssen, Endre; Hidalgo, Andres; Arranz, Lorena (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-03)
      Here we explored the role of interleukin-1β (IL-1β) repressor cytokine, IL-1 receptor antagonist (IL-1rn), in both healthy and abnormal hematopoiesis. Low IL-1RN is frequent in acute myeloid leukemia (AML) patients and represents a prognostic marker of reduced survival. Treatments with IL-1RN and the IL-1β monoclonal antibody canakinumab reduce the expansion of leukemic cells, including CD34+ ...

    • Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications 

      Arranz, Lorena; Arriero Sanchez, Maria Del Mar; Villatoro, Alicia (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-05-03)
      Interleukin-1β (IL-1β) is a pleiotropic cytokine that exerts multiple roles in both physiological and pathological conditions. It is produced by different cell subsets, and drives a wide range of inflammatory responses in numerous target cells. Enhanced IL-1β signaling is a common event in patients of hematological malignancies. Recent body of evidence obtained in preclinical models shows the ...

    • Leukemia Stem Cell Release From the Stem Cell Niche to Treat Acute Myeloid Leukemia 

      Villatoro, Alicia; Konieczny, Joanna; Cuminetti, Vincent; Arranz, Lorena (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-07-09)
      Acute myeloid leukemia (AML) is a heterogeneous, complex, and deadly disease, whose treatment has hardly evolved for decades and grounds on the use of intensive chemotherapy regimens. Chemotherapy helps reduce AML bulk, but promotes relapse in the long-run by selection of chemoresistant leukemia stem cells (LSC). These may diversify and result in progression to more aggressive forms of AML. <i>In ...

    • The role of interleukin-1 receptor antagonist in normal and malignant hematopoiesis 

      Villatoro, Alicia (Doctoral thesis; Doktorgradsavhandling, 2022-09-08)
      Interleukin-1β (IL-1β) is a pleiotropic inflammatory cytokine that exerts multiple roles in both physiological and pathological conditions. Enhanced IL-1β signaling drives hematopoietic stem cell (HSC) differentiation into the myeloid lineage and is actively involved in the development and progression of hematological malignancies, including deadly acute myeloid leukemia (AML). Inhibition of IL-1β ...